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Background: Multiple observational studies have associated antiviral treatment of patients hospitalized with
influenza with improved outcome, including reduced mortality. During the 2009–2010 H1N1 pandemic increased
use of antiviral treatment of hospital patients was reported. We have carried out prospective surveillance for
influenza in patients in a large network of Canadian hospitals since 2006. We wished to assess trends in antiviral use
in the two seasons (2010–2011 and 2011–2012) since the end of the pandemic.
Findings: Adults (>16 years) testing positive for influenza at the time of or during admission to participating Canadian
hospitals were prospectively reviewed. In 2009–2010 there were 1132 confirmed cases, 1107 in 2010–2011 and 631 in
2011–2012. Information on antiviral therapy was available in >95% in each year. Rising to 89.6% in 2009, the proportion
of adult patients treated with antiviral therapy fell to 79.9% and 65.7% in the two subsequent seasons (p < 0.001).
Oseltamivir was the antiviral agent used in >98% of cases in each year. The median time from onset of symptoms to
initiation of antiviral therapy was three days. The treatment proportion fell across all age groups, co-morbid conditions
and disease severity.
Conclusion: Despite evidence for benefit of antiviral therapy, and clinical practice guidelines recommending treatment
of this population, antiviral therapy of Canadian adults hospitalized with influenza has progressively fallen in the two
seasons since the end of the 2009–2010 influenza pandemic.Findings
Introduction
Multiple observational studies in patients hospitalized
with influenza carried out during seasonal and pandemic
influenza years have documented a survival benefit in pa-
tients treated with antiviral therapy [1-4]. Clinical practice
guidelines recommend treating all patients who are unwell
enough to be admitted to hospital [5-7]. During the 2009
pandemic, the proportion of patients treated with antiviral
therapy greatly increased in adults in US hospitals [8]. We
have carried out prospective surveillance for the occur-
rence of laboratory confirmed influenza in adults admitted
to a sentinel network of Canadian hospitals since 2006* Correspondence: geoff.taylor@ualberta.ca
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reproduction in any medium, provided the orand aimed to assess trends in antiviral use in this popula-
tion in the two influenza seasons following the end of the
2009 pandemic.
Setting and methods
The Canadian Nosocomial Infection Surveillance Program
(CNISP) is a network of 54 largely urban tertiary acute care
hospitals from ten provinces and is a partnership between
the Public Health Agency of Canada which provides fund-
ing and the Canadian Hospital Epidemiology Committee, a
sub-committee of the Association of Medical Microbiology
and Infectious Disease -Canada. We have carried out sur-
veillance for influenza in adult patients in network hospi-
tals since 2006, as previously described [9]. Briefly, from
2006 to 2008, CNISP conducted surveillance of laboratory-
confirmed influenza among hospitalized inpatients 16 yearstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Following the emergence of the pH1N1 influenza in 2009,
the program was expanded to year-round surveillance,
which continued in the post pandemic influenza seasons.
An influenza case was defined as any adult (≥ 16 years of
age) with a positive influenza laboratory test result from a
specimen collected during the surveillance period on or
during admission to a participating hospital. Cases were
identified by concurrent or retrospective chart review by
infection control practitioners. Patient questionnaires were
completed for each case. Patients were reviewed 30 days
after initial positive test to determine whether death had
occurred. Underlying medical conditions that were consist-
ently collected for the 2009–10, 2010–11 and 2011–12 sea-
sons were: chronic lung disease, chronic heart disease,
immune suppression, diabetes mellitus and kidney disease.
Descriptive statistics were calculated. Differences were
assessed for categorical variables using the Chi-squared test
and p values reflect a two-tailed alpha level of 0.05. Univar-
iate and multivariate logistic regression and survival ana-
lysis were conducted for the data from the 2009–2010
surveillance year data onwards to assess the association be-
tween antiviral therapy use and 30-day in-hospital mortal-
ity and overall mortality respectively. In order to control
for possible confounding, variables for underlying chronic
lung disease, chronic heart disease and kidney disease, as
well as age, were included in the final logistic and survival
analysis models. Missing data and unable to assess re-
sponses were removed from all calculations. Statistical ana-
lysis was performed using Stata version 11 (StataCorp,
College Station, TX) and SAS Enterprise Guide 5.1 (SAS
Institute Inc, Cary, NC).
Results
In 2009, there were 1,132 cases of influenza in 43 hospi-
tals; antiviral therapy data was available for 1,113 cases
(98.3%). In 2010–11 there were 1,107 cases in 35 hospi-
tals; antiviral therapy data was available for 1,092 cases
(98.6%). In 2011–12 there were 631 cases in 42 hospitalsFigure 1 Proportion of adult inpatients with laboratory confirmed infwith antiviral therapy information available for 604 cases
(95.7%). Oseltamivir was the antiviral agent used
in >98% of all cases in the 3 seasons. The median duration
from onset of symptoms to the start of antiviral therapy
was 3 days in each of the seasons. Figure 1 demonstrates
the trend in antiviral therapy in the hospital network from
2006–2012. After a marked increase in proportion of pa-
tients receiving antivirals in the 2009–2010 pandemic year
compared to 2006–2007 to 2008–2009 pre-pandemic sea-
sons, a significant and progressive decline in antiviral use
occurred in the two subsequent seasons, reaching 65.7%
in 2011–2012. With a few exceptions, the fall in antiviral
therapy was generalized amongst participating hospitals
(data not shown). Table 1 describes antiviral use in patient
subgroups. In the 2011–2012 season, there was a signifi-
cant decline in antiviral use in patients >65 years of age
compared to 2009–2010 season (from 82.0% to 64.3%).
There was a similar decline in treatment proportion in
every other age category: from 91% to 63% in the 50–
64 year age group, 91% to 71% in the 25–49 year age
group, and 90% to 72% in the 16–24 year age group. Sig-
nificant, and in some cases progressive declines in antiviral
use were seen in patients with a variety of co-morbid con-
ditions. For patients with any co-morbid condition, anti-
viral use fell from 89.7% in 2009 to 80.7% in 2010–2011
and 66.8% in 2011–2012. For patients ill enough to require
ICU admission, antiviral therapy fell from a peak of 94.2%
in 278 patients in 2009 to 79.5% of 78 patients in 2011–
2012 (p < 0.001).
In the three seasons from 2009–2010 to 2011–2012
there were 123 in hospital deaths where a date of death
was known (3.7% of all cases); 98 (79.6% of all deaths) re-
ceived antiviral therapy. There was no difference in anti-
viral therapy among patients who died within 30 days of
diagnosis across all three seasons (data not shown). Nei-
ther the univariate nor multivariate logistic regression
models demonstrated a significant association between
30-day mortality and antiviral therapy use against influ-
enza between the 2009–2010 and 2011–2012 surveillanceluenza who received antiviral therapy by year.
Table 1 Antiviral therapy of adults hospitalized with
influenza by age, comorbidity, severity and year
Patient subgroup 2009-2010 2010-2011 2011-2012
Chronic heart disease 138 (88.5%) 315 (81.4%) 97 (66.4%)
p = 0.045 p < 0.001
Chronic lung disease 364 (89.9%) 277 (82.9%) 123 (61.8%)
p = 0.006 p < 0.001
Chronic renal disease 65 (89.0%) 103 (83.7%) 27 (77.1%)
p = 0.305 p = 0.010
Immune suppressed 173 (91.5%) 147 (81.2%) 100 (80.0%)
p = 0.004 p = 0.003
Diabetes 153 (92.6%) 196 (82.4%) 80 (57.6%)
p = 0.003 p < 0.001
Pregnant 60 (88.2%) 28 (75.7%) 17 (73.9%)
p = 0.10 p = 0.1.
Age≥ 65 years 123 (82.0%) 607 (82.0%) 227 (64.3%)
p = 0.994 p = 0.001
ICU admission 262 (94.2%) 120 (87.6%) 62 (79.5%)
(p = 0.02) (p < 0.001)
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similar results. After controlling for the effects of age,
chronic cardiac disease, chronic lung disease and renal
disease, antiviral therapy use was not significantly associ-
ated with the likelihood of in-hospital death. An increase
in age, however, is significantly associated with an in-
creased risk of death (see Table 2).
Discussion
The basis for recommending antiviral therapy of patients
hospitalized with influenza is derived from multiple ob-
servational studies which have demonstrated a clinical
benefit in treatment of this population, including re-
duced mortality. This benefit has been documented for
seasonal and pandemic influenza, and in ICU as well as
non-ICU patients. Our data did not demonstrate an as-
sociation between antiviral therapy and reduced risk of
in hospital risk adjusted mortality in the pandemic and





No chronic heart disease (reference chronic heart disease)
No chronic lung disease (reference chronic lung disease)
No kidney disease (reference kidney disease)
Note: HR = hazard ratio, CI = confidence interval.of deaths in the three seasons, and numbers of patients
who died who had not been treated with antiviral ther-
apy were quite low (123 and 25 respectively).
While there is strong evidence for better clinical efficacy
if antiviral therapy is initiated early, there is some evidence
for clinical efficacy even when treatment is delayed up to
5 days following onset of illness; on theoretical grounds
treatment may be effective in some subgroups when
started even later [10]. Based on these data , the Infectious
Diseases Society of America (IDSA), and its Canadian
counterpart, the Association for Medical Microbiology
and Infectious Diseases - Canada strongly recommend the
use of antiviral therapy in all patients unwell enough to be
hospitalized when treatment can be started early in the
course of the illness, and recommend it when the diagno-
sis is made late in the course [6,7].
In our hospital network, as in US hospitals, the pro-
portion of cases admitted to hospital that were treated
with antiviral agents greatly increased during the 2009
pandemic year. It is therefore disconcerting to find that
the gains in treatment have been substantially lost in the
post pandemic period. Garg et al. demonstrated a 6% de-
cline in antiviral therapy of adults admitted to US hospi-
tals from 82% during the pandemic, to 77% in the first
post pandemic year [11]. Our data illustrates a more pre-
cipitate and progressive trend in patients hospitalized in
Canadian hospitals, from the peak of 89.6% during the
pandemic to only 65.7% in the second post pandemic
year. This trend was widespread affecting all age groups,
including the elderly, and all underlying co-morbid con-
ditions. Furthermore it was also experienced by patients
sick enough to require ICU admission.
Given the consensus that hospitalized patients should
be treated, reasons for the declining use of antiviral ther-
apy are not clear. The decline in enthusiasm for treatment
may in part be driven by controversy around efficacy of
antiviral therapy based on clinical trials data. Randomized
trials of antiviral therapy, primarily oseltamivir, have
undergone recent re-examination raising doubt regarding
the clinical benefit of treatment [12]. However, these trials
are not directly relevant to hospitalized patients, since they
were conducted largely on otherwise healthy ambulatory
patients.age, chronic heart disease, chronic lung disease and
p-value HR*- (95% CI)
0.63 1.12 (0.72, 1.74)
<0.001 1.02 (1.01, 1.03)
0.16 1.33 (0.90, 1.97)
0.93 0.98 (0.68, 1.42)
0.07 0.65 (0.42, 1.03)
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curred in the context of a pandemic and represented a
marked increased compared with previous seasons. The
subsequent decrease may represent a gradual return to the
pre-pandemic healthcare worker behavior, or a perception
that seasonal influenza, even in hospitalized patients, may
be of lesser severity. This suggests that the effect of the in-
tensive training and promotion that were conducted in
the context of the pandemic was short-lived.
Conclusion
In the two seasons following the 2009 pandemic, the pro-
portion of patients hospitalized with influenza treated with
antiviral therapy in Canada has markedly declined. Further
research should be carried out to understand the reasons
for declining treatment rates. Promotion of antiviral use in
hospitalized patients may need to be repeated in order to
obtain a sustained effect and to prevent further decrease
in use.
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